Eikon Therapeutics, Inc. (NASDAQ:EIKN) Given Average Rating of “Hold” by Analysts

Eikon Therapeutics, Inc. (NASDAQ:EIKN) has received an average rating of “Hold” from the eight analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $25.20.

A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Eikon Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, April 5th. Weiss Ratings started coverage on shares of Eikon Therapeutics in a research report on Monday, June 1st. They set a “sell (e-)” rating for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a research note on Tuesday, June 2nd. Finally, Wedbush dropped their price objective on shares of Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating on the stock in a research note on Tuesday, May 12th.

Eikon Therapeutics Price Performance

NASDAQ EIKN opened at $12.54 on Friday. The company has a market capitalization of $678.90 million and a price-to-earnings ratio of -5.10. The company’s 50 day moving average price is $10.32. Eikon Therapeutics has a twelve month low of $7.90 and a twelve month high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN) last posted its quarterly earnings data on Monday, March 30th. The company reported ($26.23) earnings per share (EPS) for the quarter.

Eikon Therapeutics Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.